Drugs / JLP-1310
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03690778 | Oct 2018 → Feb 2019 | diabetes mellitus, hyperlipidemia | Jeil Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02449187 | Aug → Sep 2017 | diabetes mellitus, hyperlipidemia | Jeil Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02982798 | Jul → Aug 2017 | diabetes mellitus, hyperlipidemia | Jeil Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JLP-1310 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03690778 ↗ |
| Route | Oral | “the subjects will receive an oral pill of JLP-1310” NCT02449187 ↗ |